Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00123630
Other study ID # 13623
Secondary ID
Status Completed
Phase Phase 2
First received July 21, 2005
Last updated May 18, 2016
Start date November 2005
Est. completion date January 2010

Study information

Verified date March 2016
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults.

The pathophysiology of EE appears to be an allergy/atopy mediated disease. A personal and family history of allergic diseases (food allergies, atopic dermatitis, asthma, allergic rhinitis or conjunctivitis) has been noted in 62-85% of patients with EE. The rising incidence of EE may be related to the worldwide allergy and asthma epidemic.

Current treatment of EE is directed at decreasing esophageal allergic inflammation. Oral and topical corticosteroids, cromolyn sodium, montelukast and elemental/elimination diets have all been shown to be effective. However, none of these treatments are directed at the specific pathophysiologic mechanism of EE and some have significant side effects.

The shared pathogenetic mechanisms of EE and asthma suggest that therapeutic strategies directed at asthma may also be effective for EE. Specifically those targeted at the allergic immune mechanisms involved with asthma may be effective. Omalizumab is a recently developed anti-IgE antibody that has been shown to decrease the use of inhaled and oral corticosteroids, reduce the frequency of asthma exacerbations, and improve asthma related symptoms in patients with allergic asthma. The objective of the study is to determine the efficacy of omalizumab in the treatment of eosinophilic esophagitis


Description:

This is a dual-center double-blind, placebo controlled trial of omalizumab for the treatment of EE. Omalizumab will be dosed depending on the patient's body weight and baseline IgE level. Omalizumab or placebo will be administered subcutaneously every 4 weeks for 16 weeks. At study entry subjects will have EGD with biopsies performed to ensure the diagnosis and obtain tissue for histologic analysis. No dilation will be performed at this time. Baseline validated questionnaires for dysphagia, GERD, and atopy will also be administered. Blood will be drawn for baseline serum testing. Repeat questionnaires and rating of overall symptom improvement will be administered at 4 week intervals for the rest of the study period. At the end of the 16 week period, repeat endoscopy will be performed and biopsies taken. Esophageal dilation may be performed if clinically indicated at this time. Blood will also be drawn for repeat serum testing.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Both
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria:

- Male or female subjects aged 12-60 years of age with EE as defined above

- Serum IgE level 30-700 IU/mL

- Subjects with acceptable medical history, physical exam and laboratory test results

- No history of bleeding diathesis, significant cardiopulmonary disease, or other contraindication to upper endoscopy

Exclusion Criteria:

- Need for esophageal dilation at enrollment due to food impaction or inability to pass endoscope

- Inability of subject to provide informed consent (if ages 18-60), or inability of children (ages 12-17) to provide assent

- History of esophagogastric surgery

- Presence of other esophageal pathology that could account for patients' symptoms including eosinophil infiltration due to gastroesophageal reflux disease (GERD)

- Incarceration

- Pregnancy

- Women of childbearing potential not using the contraception method(s)

- Patients with elevated serum IgE levels for reasons other than atopy

- Patients taking cromolyn sodium or nedocromil sodium within 1 month of visit 1

- Patients taking oral or topical corticosteroids within one month of visit 1

- Patients taking leukotriene receptor inhibitors within one month of visit 1

- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study

- Patients with a history of noncompliance to medical regimens or who were considered potentially unreliable

- Use of any other investigational agent in the last 30 days

- Patients with a known hypersensitivity to any ingredient of rhuMAb-E25, study rescue medication

- Patients with Barrett's esophagus will be excluded if found endoscopically or pathologically at biopsy

- Currently treated with omalizumab or treated with omalizumab within the past 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
omalizumab
omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
Placebo
Placebo given IV once every 2-4 weeks based on weight

Locations

Country Name City State
United States University of Utah HSC Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
University of Utah Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups 16 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00284908 - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Phase 1
Completed NCT00272818 - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Recruiting NCT05326113 - The Effect of Physiotherapy on Post POEM Reflux N/A
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Terminated NCT02575391 - The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer Phase 1/Phase 2
Completed NCT00256529 - Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia N/A
Completed NCT00081315 - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Phase 2
Completed NCT00471094 - Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis Phase 2
Completed NCT00579410 - Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule N/A
Recruiting NCT05109819 - Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression. N/A
Withdrawn NCT01824199 - CYP2C19 Genotype Predictor of Gastric Acid Suppression Early Phase 1
Completed NCT01556919 - Esophageal Monitoring Device for Assessing Mucosal Impedance
Active, not recruiting NCT03835663 - The Bacterial Composition of the Stomach in Reflux Disease
Completed NCT00195208 - Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis Phase 3
Completed NCT00175045 - Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis Phase 2
Completed NCT05129670 - Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum N/A
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Completed NCT03228147 - Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment N/A
Completed NCT01322633 - Risk of Cancer Among Pantoprazole Users N/A
Completed NCT00133770 - Intravenous (IV) Pantoprazole in Erosive Esophagitis Phase 4